Pediaric Cancer Genome Project Makes Data Available To All

The Pediatric Cancer Genome Project has released the full genomes of over 500 normal and cancerous tumor tissue samples, with a view towards encouraging research against childhood cancers. Instantly, the wealth of knowledge on whole genome data doubles with this release.

Of the some 10,000 childhood cancer diagnoses made annually in the United States, over half affect the central nervous system (including the brain) as well as leukemias. According to National Cancer Institute statistics, up to 1,500 chlidren succumb to cancer each year.

Genome data will benefit many fields

While the genomic information likely most benefits cancer researchers, in fact scientists from many medical fields will benefit from this information.

In a press release, Dr. James Downing, the scientific director of St. Jude Children's Research Hospital, wrote:

"This effort has generated more discoveries than we thought possible. We want to make this information available to the broader scientific community so that, collectively, we can explore new treatment options for these children. By sharing the information even before we analyze it ourselves, we're hoping that other researchers can use this rich resource for insights into many other types of diseases in children and adults."

The almost entirely privately funded Cancer Genome Project costing $65 million, was initially launched in 2010. The data appears in the current issue of the journal Nature Genetics.

Source: PCGP

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap